Skip to main content

Advertisement

Table 1 Main clinical, metabolic data, medical treatment and atheromatous disease characteristics in the study population according to the presence of prediabetes

From: Characteristics of atheromatosis in the prediabetes stage: a cross-sectional investigation of the ILERVAS project

 Prediabetes (n = 2269)Control group (n = 4419)p
Women, n (%)1290 (56.9)2151 (48.7)< 0.001
Age (years)59 [54;64]57 [52;62]< 0.001
HbA1c (mmol/mol)40 [39;42]36 [33;37]< 0.001
HbA1c (%)5.8 [5.7;6.0]5.4 [5.2;5.5]< 0.001
Dyslipidemia, n (%)1290 (56.9)2214 (50.1)< 0.001
 Total cholesterol (mg/dL)206 [183;231]203 [179;229]0.002
 LDL-cholesterola (mg/dL)146 [133;164]145 [129;162]0.020
 HDL-cholesterola (mg/dL)53 [45;65]55 [46;67]0.009
 Triglyceridesa (mg/dL)148 [113;205]133 [100;183]< 0.001
 Lipid-lowering agents, n (%)534 (23.5)712 (16.1)< 0.001
 Statins, n (%)478 (21.0)656 (14,8)< 0.001
 Fibrates, n (%)62 (2.7)54 (1.2)< 0.001
 Ezetimibe, n (%)8 (0.3)17 (0.3)0.838
 Omega-3 fatty acids, n (%)6 (0.2)0 (0.0)0.001
Hypertension, n (%)1048 (46.2)1617 (36.6)< 0.001
 Systolic BP (mm Hg)132 [120;142]129 [119;141]< 0.001
 Diastolic BP (mm Hg)81 [75;88]81 [75;88]0.764
 Pulse pressure (mm Hg)49 [42;58]47 [40;56]< 0.001
 Antihypertensives, n (%)911 (40.1)1305 (29.5)< 0.001
 ACE inhibitors, n (%)430 (18.9)659 (14.9)< 0.001
 ARA II, n (%)230 (10.1)334 (7.5)< 0.001
 Diuretics, n (%)441 (19.4)586 (13.2)< 0.001
 Beta-blockers, n (%)196 (8.6)216 (4.8)< 0.001
 Calcium antagonists, n (%)147 (6.4)210 (4.7)0.003
 Other, n (%)12 (0.5)19 (0.4)0.573
Obesityb, n (%)817 (36.0)1176 (26.6)< 0.001
 BMI (kg/m2)29.6 [26.7;33.1]28.0 [25.1;31.2]< 0.001
Current or former smoker, n (%)1211 (53.4)2714 (61.4)< 0.001
Antithrombotics, n (%)94 (4.1)115 (2.6)0.001
Number of CV risk factors2 [1;3]2 [1;2]< 0.001
Characteristics of atheromatous disease
 Presence of any plaque, n (%)1597 (70.4)2984 (67.5)0.017
 Carotid territory affected, n (%)1112 (49.0)1924 (43.5)< 0.001
 Femoral territory affected, n (%)1227 (54.1)2321 (52.5)0.228
 Number of affected territories2 [1;3]1 [0;3]0.002
 Total plaque area, (cm2)0.96 [0.52;1.62]0.93 [0.56;1.55]0.760
 Stenotic lesions ≥ 50%21 (0.9)23 (0.5)0.057
  1. Data are expressed as a median [interquartile range] or n (percentage)
  2. HbA1c glycosylated hemoglobin, LDL low density lipoprotein, HDL high density lipoprotein, BP blood pressure, BMI body mass index, CV cardiovascular
  3. aDetermination was done in cases in which total cholesterol was ≥ 200 mg/dL and after fasting for 6 h or total cholesterol ≥ 250 mg/dL regardless of fasting hours
  4. bObesity was defined as a BMI ≥ 30 kg/m2